Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.
Gemcitabine (2,2-difluorodeoxycytidine, dFdC) is a prodrug widely used for treating various carcinomas. Gemcitabine exerts its clinical effect by depleting the deoxyribonucleotide pools, and incorporating its triphosphate metabolite (dFdC-TP) into DNA, thereby inhibiting DNA synthesis. This process...
Guardado en:
Autores principales: | Ozan Kahramanoğullari, Gianluca Fantaccini, Paola Lecca, Daniele Morpurgo, Corrado Priami |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b33cbb15a1c647dab4e2a072cf1accb3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong DJ, et al.
Publicado: (2013) -
Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism
por: Mahya Mehrmohamadi, et al.
Publicado: (2016) -
Attitude Estimation Algorithm of Portable Mobile Robot Based on Complementary Filter
por: Mei Liu, et al.
Publicado: (2021) -
Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
por: Makoto Isono, et al.
Publicado: (2021) -
Quantifying cerebral contributions to pain beyond nociception
por: Choong-Wan Woo, et al.
Publicado: (2017)